MVA-BN Brachyury TRICOM vaccine - Bavarian Nordic/National Cancer Institute

Drug Profile

MVA-BN Brachyury TRICOM vaccine - Bavarian Nordic/National Cancer Institute

Alternative Names: BN-Brachyury; Brachyury/TRICOM; MVA-BN-Brachyury vaccine; MVA-BN-Brachyury/ FPV-Brachyury; MVA-brachyury-TRICOM

Latest Information Update: 07 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bavarian Nordic; National Cancer Institute (USA)
  • Developer National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chordoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 02 May 2018 MVA-BN Brachyury TRICOM vaccine receives Orphan Drug status for Chordoma in USA
  • 01 May 2018 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (SC) (NCT03493945)
  • 11 Apr 2018 National Cancer Institute plans the QuEST1 phase I/II trial for Solid tumours and Prostate cancer in USA (NCT03493945)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top